T2D and binge-eating disorder: dulaglutide reduces binge-eating behavior

  • Da Porto A & al.
  • Diabetes Metab Syndr
  • 31 Mar 2020

  • curated by Miriam Tucker
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In pilot study, dulaglutide reduced binge eating (BE) in patients with type 2 diabetes (T2D) and BE disorder (BED), accompanied by reductions in body weight and HbA1c.  
  • Glucagon-like peptide-1 analogues might be a treatment of choice in these patients.

Why this matters

  • BED presence and severity as assessed by the BE Scale (BES) are associated with worse metabolic control and greater difficulty in reaching T2D treatment targets.

Study design

  • Pilot open-label, prospective, controlled study of 60 patients (32 females) age ≤65 years with HbA1c between 7.5% and 9% on metformin alone, normal renal function, and BED diagnosis randomly assigned to dulaglutide 150 mg/week or gliclazide modified release 2-3 g/day.
  • Funding: None disclosed.

Key results

  • After 12 weeks of treatment, both groups had significant HbA1c percentage point reductions:
    • −1.073 dulaglutide.
    • −0.753 gliclazide.
    • P=.009 between groups.
  • With dulaglutide vs gliclazide, significant decreases in:
    • Body weight: −4.767 vs 0.073 kg (P<.0001>
    • BMI: −1.653 vs 0.040 kg/m2 (P<.0001>
    • Percentage body fat mass: −1.850% vs 0.197% (P<.0001>
    • BES score: −12.067 vs −0.467 points (P<.0001>
  • In multivariate analysis, BES score decrease was directly related to changes in body weight (P<.0001 hba1c independently of treatment type.>
  • No gastrointestinal side effects reported.

Limitations

  • Small sample size.
  • Short duration.